Legend Biotech (LEGN)
(Delayed Data from NSDQ)
$40.03 USD
+0.02 (0.05%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $40.05 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Legend Biotech Corporation Sponsored ADR [LEGN]
Reports for Purchase
Showing records 21 - 34 ( 34 total )
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
DLL-3 Deal With Novartis Validates LB2102 and Pipeline; Raising PT to $87
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
We See Little Threat to Carvykti from CART-ddBCMA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
Another Impressive Carvykti Sales Growth Quarter; Raising PT to $86
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
New Myeloma Drugs Do Not Impact CARVYKTI, In Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
Carvykti Growth Continues to Accelerate; Raising PT to $85
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
Label Extension Filing Submitted to FDA for Early-Line Myeloma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
CARTITUDE-4 Trial Hits Home Run in Multiple Myeloma; Raising PT to $82
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
Carvykti Sales Growth Projected in 2023; 1Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
Strong CARTITUDE-4 Data; Carvykti Sales Growth Impresses; Raising PT to $77
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
Novartis Manufacturing Deal To Expand Carvykti Supply; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
Addition of Chief Medical Officer Fortifies Clinical Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
Supply Limit Alleviation to Drive Growth; 2022 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Legend Biotech Corporation Sponsored ADR
Industry: Medical - Biomedical and Genetics
Moving Mountains in Myeloma and Beyond; Initiating at Buy and $66 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M